Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Sucrase is a digestive enzyme that breaks down sucrose. Prescribed as Sucraid for congenital sucrase-isomaltase deficiency (CSID). As a supplement, it is very safe. Individuals with hereditary fructose intolerance should avoid. No drug interactions at standard doses.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Enzymes
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Sucrase indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 ივნ 2026, 12:03
Evidence Distribution
-
Observational / other LOW evidence YELLOWA call for caution in expanding the mutational spectrum of SI gene deficiency. ↗Spurnu00e1 Z et al.. A call for caution in expanding the mutational spectrum of SI gene deficiency.. Scand J Gastroenterol. 2026. PMID:42223142.PMID 42223142 ↗Journal Scand J GastroenterolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42223142/
-
Observational / other LOW evidence YELLOWEfficient U(VI) immobilization of uranium-contaminated soil mediated by Fungal-Bacterial Consortia. ↗Wang X et al.. Efficient U(VI) immobilization of uranium-contaminated soil mediated by Fungal-Bacterial Consortia.. J Hazard Mater. 2026. PMID:42214860.PMID 42214860 ↗Journal J Hazard MaterYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42214860/
-
Observational / other LOW evidence YELLOWAlfalfa Rotation Enhances Soil Microbial Diversity and Reduces Tilletia foetida DNA Abundance in Common Bunt-Infected Wheat Fields. ↗Chen D et al.. Alfalfa Rotation Enhances Soil Microbial Diversity and Reduces Tilletia foetida DNA Abundance in Common Bunt-Infected Wheat Fields.. Plant Pathol J. 2026. PMID:42210638.PMID 42210638 ↗Journal Plant Pathol JYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42210638/
-
Observational / other LOW evidence YELLOWAssessment of the Impacts of Common Morel (Morchella sextelata) Cultivation on Soil Physicochemical Properties and Microbial Communities in Different Environments. ↗Tang Z et al.. Assessment of the Impacts of Common Morel (Morchella sextelata) Cultivation on Soil Physicochemical Properties and Microbial Communities in Different Environments.. Microorganisms. 2026. PMID:42197500.PMID 42197500 ↗Journal MicroorganismsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42197500/
-
Observational / other LOW evidence YELLOWIsolation and Identification of an Endophytic Fungus Aspergillus sp. and Its Growth-Promoting Effects on Nymphaea candida Seedlings Through Modulation of the Rhizosphere… ↗Xing Y et al.. Isolation and Identification of an Endophytic Fungus Aspergillus sp. and Its Growth-Promoting Effects on Nymphaea candida Seedlings Through Modulation of the Rhizosphere Microbial Community.. Microorganisms. 2026. PMID:42197380.PMID 42197380 ↗Journal MicroorganismsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42197380/
-
Observational / other LOW evidence YELLOWSucrase-Isomaltase Deficiency in Children with Functional Gastrointestinal Disorders. ↗Demirci FK et al.. Sucrase-Isomaltase Deficiency in Children with Functional Gastrointestinal Disorders.. J Clin Med. 2026. PMID:42194600.PMID 42194600 ↗Journal J Clin MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42194600/
-
Observational / other LOW evidence YELLOWDietary Taurine Enhances Intestinal Digestion, Absorption, and Villus Morphology in Mice. ↗Kong J et al.. Dietary Taurine Enhances Intestinal Digestion, Absorption, and Villus Morphology in Mice.. Animals (Basel). 2026. PMID:42193794.PMID 42193794 ↗Journal Animals (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42193794/
-
Observational / other LOW evidence YELLOWPotent sucrase inhibition by purple sweet potato anthocyanins for glycemic control: unveiling peonidin-3-caffeoyl-feruloylsophoroside-5-glucoside as the key functional monomer and its interaction mechanism. ↗Li J et al.. Potent sucrase inhibition by purple sweet potato anthocyanins for glycemic control: unveiling peonidin-3-caffeoyl-feruloylsophoroside-5-glucoside as the key functional monomer and its interaction mechanism.. Food Chem. 2026. PMID:42184515.PMID 42184515 ↗Journal Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42184515/
-
Observational / other LOW evidence YELLOWInhibitory mechanism of Tangzhiqing on sucrase: changed inhibitory kinetics and secondary molecular conformation of sucrase and chemical components from Tangzhiqing. ↗Li Y et al.. Inhibitory mechanism of Tangzhiqing on sucrase: changed inhibitory kinetics and secondary molecular conformation of sucrase and chemical components from Tangzhiqing.. BMC Complement Med Ther. 2026. PMID:42129756.PMID 42129756 ↗Journal BMC Complement Med TherYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42129756/
-
Observational / other LOW evidence YELLOWInterfacial charge-transfer-driven uptake and reduction of hexavalent chromium on amine-functionalized bentonite: mechanistic insights into surface chemistry and electron-transfer processes. ↗Zhang Y et al.. Interfacial charge-transfer-driven uptake and reduction of hexavalent chromium on amine-functionalized bentonite: mechanistic insights into surface chemistry and electron-transfer processes.. J Environ Manage. 2026. PMID:42114404.PMID 42114404 ↗Journal J Environ ManageYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42114404/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Sucrase. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Sucrase
A score of 1.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.